Literature DB >> 1692084

Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide.

P Aichele1, H Hengartner, R M Zinkernagel, M Schulz.   

Abstract

Induction in vivo of antiviral cytotoxic T cell response was achieved in a MHC class I-dependent fashion by immunizing mice three times with a free unmodified 15-mer peptide derived from the nucleoprotein of lymphocytic choriomeningitis virus in IFA. The effector T cells are CD8+, restricted to the class I Ld allele of the analyzed mouse strain, and are specific both at the level of secondary restimulation in vitro and at the effector T cell level. These results suggest that cocktails of viral peptides may be used as antiviral T cell vaccines.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1692084      PMCID: PMC2187909          DOI: 10.1084/jem.171.5.1815

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  15 in total

1.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides.

Authors:  A R Townsend; J Rothbard; F M Gotch; G Bahadur; D Wraith; A J McMichael
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

2.  In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine.

Authors:  K Deres; H Schild; K H Wiesmüller; G Jung; H G Rammensee
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

3.  Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo.

Authors:  G Y Ishioka; S Colon; C Miles; H M Grey; R W Chesnut
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

4.  Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity.

Authors:  J L Whitton; A Tishon; H Lewicki; J Gebhard; T Cook; M Salvato; E Joly; M B Oldstone
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

5.  Major histocompatibility complex--dependent T cell epitopes of lymphocytic choriomeningitis virus nucleoprotein and their protective capacity against viral disease.

Authors:  M Schulz; P Aichele; M Vollenweider; F W Bobe; F Cardinaux; H Hengartner; R M Zinkernagel
Journal:  Eur J Immunol       Date:  1989-09       Impact factor: 5.532

Review 6.  Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes.

Authors:  T J Braciale; L A Morrison; M T Sweetser; J Sambrook; M J Gething; V L Braciale
Journal:  Immunol Rev       Date:  1987-08       Impact factor: 12.988

7.  Cytotoxic T lymphocytes against a soluble protein.

Authors:  U D Staerz; H Karasuyama; A M Garner
Journal:  Nature       Date:  1987 Oct 1-7       Impact factor: 49.962

8.  p-alkoxybenzyl alcohol resin and p-alkoxybenzyloxycarbonylhydrazide resin for solid phase synthesis of protected peptide fragments.

Authors:  S S Wang
Journal:  J Am Chem Soc       Date:  1973-02-21       Impact factor: 15.419

9.  Class I MHC can present an endogenous peptide to cytotoxic T lymphocytes.

Authors:  J L Whitton; M B Oldstone
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

10.  Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization.

Authors:  F R Carbone; M J Bevan
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  56 in total

1.  Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis.

Authors:  G Dadaglio; Z Moukrim; R Lo-Man; V Sheshko; P Sebo; C Leclerc
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

2.  In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity.

Authors:  C Sedlik; G Dadaglio; M F Saron; E Deriaud; M Rojas; S I Casal; C Leclerc
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity.

Authors:  C Fayolle; A Osickova; R Osicka; T Henry; M J Rojas; M F Saron; P Sebo; C Leclerc
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Skin test to assess virus-specific cytotoxic T-cell activity.

Authors:  T M Kündig; A Althage; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

Review 5.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

6.  Cognate peptides induce self-destruction of CD8+ cytolytic T lymphocytes.

Authors:  P R Walden; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

7.  Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model.

Authors:  P Aichele; D Kyburz; P S Ohashi; B Odermatt; R M Zinkernagel; H Hengartner; H Pircher
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

8.  Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein.

Authors:  A Bertoletti; F V Chisari; A Penna; S Guilhot; L Galati; G Missale; P Fowler; H J Schlicht; A Vitiello; R C Chesnut
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain.

Authors:  J N Flynn; C A Cannon; G Reid; M A Rigby; J C Neil; O Jarrett
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

10.  Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus.

Authors:  X Zhou; P Berglund; H Zhao; P Liljeström; M Jondal
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.